国际队列中肌张力障碍的药物治疗模式
该横断面分析纳入国际生物样本库研究中37个中心的2026例肌张力障碍患者,评估推荐药物类别的使用频率。结果显示73%使用药物,61%使用肉毒毒素,用药模式随肌张力障碍类型、地区和局灶亚型而异。
要点
- 73%的肌张力障碍患者使用药物治疗,61%使用肉毒毒素单用或联用。
- 口服药物使用率在局灶性肌张力障碍最低、全身性最高。
- 肉毒毒素治疗率意大利最高、美国东北部最低,眼睑痉挛和痉挛性发声障碍单用率最高(49%)。
核心结论
- 多数肌张力障碍患者使用药物治疗,用药模式复杂,受地区、病程、类型、严重程度和精神共病影响。
研究设计与样本
- 横断面分析纳入美国、加拿大、欧洲和澳大利亚37个中心的2026例肌张力障碍患者,来自Dystonia Coalition Project 1国际生物样本库研究。
主要发现
- 73%使用肌张力障碍药物(n=1488),27%未使用(n=538)。
- 61%使用肉毒毒素单用或联用。
- 口服药物使用率局灶性肌张力障碍最低、全身性最高。
- 肉毒毒素治疗率意大利最高、美国东北部最低。
- 眼睑痉挛和痉挛性发声障碍单用肉毒毒素率最高(49%),其他颅部肌张力障碍最低(32%)。
临床怎么用
- 临床选择肌张力障碍药物时需考虑类型、地区实践差异、病程、严重程度和精神共病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the frequency of medication use in patients with dystonia enrolled in an international biorepository study. METHODS: In a cross-sectional analysis, we included 2,026 participants enrolled at 37 sites in the United States, Canada, Europe, and Australia through Project 1 of the Dystonia Coalition, an international biorepository study. The primary aim was to assess the frequency of medication classes recommended for treating patients with dystonia, and the secondary aim was to compare characteristics (disease type, age, sex, duration of disease, comorbid conditions, severity). RESULTS: Querying the database for the presence of any medication for dystonia used (includes both injectable and oral therapy), we found 73% using medications (n = 1,488) and 27% using no dystonia medications (n = 538). Furthermore, 61% of the total sample used botulinum toxin (BoNT) therapy alone or in combination. Differences were found in medication use patterns by dystonia type, with the lowest oral medication use in focal dystonia and highest use in generalized dystonia; by region, with highest BoNT therapy rate reported in Italy and the lowest in the Northeast region of the United States; and by focal dystonia subtype, with highest BoNT therapy alone in blepharospasm and spasmodic dysphonia (49%) and lowest in other cranial dystonia (32%). CONCLUSIONS: The majority of patients with dystonia enrolled in the Dystonia Coalition Project 1 were using medications to treat their dystonia. Overall, a complex picture of medication use patterns emerged, with factors such as region, disease duration, type of dystonia, disease severity, and psychiatric comorbidities all playing a significant role.
引用
- Pirio Richardson S, Wegele AR, Skipper B, et al. Dystonia treatment: Patterns of medication use in an international cohort. Neurology. 2017. PMID: 28077492. doi:10.1212/WNL.0000000000003596
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。